ライフサイエンスコーパス: cyclin-dependent kinase inhibitor

1 a70kb) mice is prevented by treatment with a cyclin-dependent kinase inhibitor.

2 ell-cycle arrest and accumulation of the p27 cyclin-dependent kinase inhibitor.

3 Flavopiridol is a protein bound, cytotoxic, cyclin-dependent kinase inhibitor.

4 activity and the expression level of p16, a cyclin-dependent kinase inhibitor.

5 pecificity between a GHV cyclin and a single cyclin-dependent kinase inhibitor.

6 reased apoptosis and decreased expression of cyclin-dependent kinase inhibitors.

7 27(Kip1) , a member of the Kip/Cip family of cyclin-dependent kinase inhibitors.

8 , together with the induction of p21 and p27 cyclin-dependent kinase inhibitors.

9 Ecad- subpopulation through the induction of cyclin-dependent kinase inhibitors.

10 cyclin expression and elevated expression of cyclin-dependent kinase inhibitors.

11 way-directed agents such as flavopiridol and cyclin-dependent kinase inhibitors.

12 In the absence of Jdp2, a complex of the cyclin-dependent kinase inhibitor 1 (p21(Cip1)) and Nrf2

13 on of p53 target genes, most prominently the cyclin-dependent kinase inhibitor 1 encoding cell cycle

14 feration (miR20b, miR10b, and miR141 through cyclin-dependent kinase inhibitor 1 or CDK-interacting p

15 phase, and induces expression of p(21CIP1) (cyclin-dependent kinase inhibitor 1), and p(27KIP1) (cyc

16 logical functions of p21, the product of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene, with

17 The BRCA2 DNA repair associated (BRCA2) and cyclin-dependent kinase inhibitor 1A (CDKN1A) interactin

18 Expression levels of the Cyclin-dependent kinase inhibitor 1a (CDKN1A), Growth/di

19 dramatically up-regulated the mRNA encoding cyclin-dependent kinase inhibitor 1a (Cdkn1a).

20 ed by short-term NEUROG3 expression required cyclin-dependent kinase inhibitor 1A (CDKN1A)/p21(CIP1)

21 re, we show that loss of the p53 target gene cyclin-dependent kinase inhibitor 1A (CDKN1A, also known

22 ecies and p38 MAPK-dependent upregulation of cyclin-dependent kinase inhibitor 1A (Cdkn1a, encoding f

23 l-cycle genes, and we identified the mRNA of cyclin-dependent kinase inhibitor 1A (Cdkn1a, p21) as a

24 Among the tested miR-17 targets, the cyclin-dependent kinase inhibitor 1A (p21) was up-regula

25 R-34 family, TP53 gene, downstream effectors cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A

26 e stem cell (HFSC) homeostasis and find p21 (cyclin-dependent kinase inhibitor 1a, Cdkn1a), p57, and

27 pathways; and residual hepatocytes overcame cyclin-dependent kinase inhibitor 1A-induced cell growth

28 is led to liver cell growth arrest involving cyclin-dependent kinase inhibitor 1A.

29 behavior through repression of two targets: cyclin dependent kinase inhibitor 1b (cdkn1b) and phosph

30 echanism was identified as downregulation of cyclin-dependent kinase inhibitor 1B (p27(Kip1)) via upr

31 e B-cell CLL/lymphoma 2 or xL (Bcl-2/xL) and cyclin-dependent kinase inhibitor 1B (P27) protein level

32 ependent kinase inhibitor 1), and p(27KIP1) (cyclin-dependent kinase inhibitor 1B) expression, key ce

33 ad markedly decreased quiescence and reduced cyclin-dependent kinase inhibitor 1b/c (Cdkn1b/1c) expre

34 is-derived transcript), the tumor suppressor cyclin-dependent kinase inhibitor 1C (CDKN1C; p57KIP2),

35 olutionarily conserved cell-cycle regulator, cyclin-dependent kinase inhibitor 1d (20 kDa protein, p2

36 genes phosphatase and tensin homolog (PTEN), cyclin dependent kinase inhibitor 2A (CDKN2A), LKB1, and

37 identifying the well-known tumor suppressor cyclin dependent kinase inhibitor 2A (Cdkn2a), whose alt

38 overexpression is concomitant with a loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) locus (enc

39 tions of knockdowns of the tumor suppressors cyclin-dependent kinase inhibitor 2A (Cdkn2a), transform

40 Furthermore, T-box (TBX) genes and cyclin-dependent kinase inhibitor 2A (CDKN2A), which are

41 BRAF(V600E)) in association with homozygous cyclin-dependent kinase inhibitor 2A (CDKN2A, encoding p

42 sistent microbial insult (e.g. LPSs) induces cyclin-dependent kinase inhibitor 2A (CDKN2A/p16(INK4a))

43 iral oncogene [Kras(G12V)] and disruption of cyclin-dependent kinase inhibitor 2A (CDKN2A; p16p19) in

44 on through derepression of the gene encoding cyclin-dependent kinase inhibitor 2a (INK4a).

45 d III transcription, and thyroxine decreased cyclin-dependent kinase inhibitor 2A (p16(ink4)) express

46 by a mechanism that involved suppression of cyclin-dependent kinase inhibitor 2A (p16INK4A) expressi

47 tivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cad

48 ers associated with repression of p16(INK4a)/cyclin-dependent kinase inhibitor 2A(CDKN2A), a critical

49 (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin

50 essor genes RB1 (retinoblastoma) and CDKN2a (cyclin-dependent kinase inhibitor 2a) are critical cell-

51 Increased expression of CDKN2A (cyclin-dependent kinase inhibitor 2A)-a downstream targe

52 d by another major POAG risk gene, p16INK4a (cyclin-dependent kinase inhibitor 2A, isoform INK4a).

53 tion and 3-fold hypomethylation of the human cyclin-dependent kinase inhibitor 2B (CDKN2B or p15) gen

54 at loss of one candidate gene at this locus, cyclin-dependent kinase inhibitor 2B (Cdkn2b), in mice p

55 factor beta (TGFbeta) signaling in cultured cyclin-dependent kinase inhibitor 2B (CDKN2B)-deficient

56 hypoxia inducible factor 1A antisense RNA 2, cyclin-dependent kinase inhibitor 2B antisense RNA 1 (AN

57 or STAT5, enhances expression of the Cdkn2b (cyclin-dependent kinase inhibitor 2B) gene and that STAT

58 n-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many o

59 h Cyclin D1 and Cyclin D2, and the p27(Kip1) cyclin-dependent kinase inhibitor act downstream of Notc

60 be reversed by treatment with roscovitine, a cyclin-dependent kinase inhibitor and atypical L-type-ch

61 CDKN1C is a cyclin-dependent kinase inhibitor and is a candidate tum

62 ociated with reduced levels of the p21(Cip1) cyclin-dependent kinase inhibitor and tumor suppressor p

63 This was accompanied by upregulation of cyclin-dependent kinase inhibitors and a significant cel

64 w targets and associated therapeutic agents: cyclin-dependent kinase inhibitors and poly(adenosine di

65 of the cell cycle, decreasing expression of cyclin-dependent kinase inhibitors and upregulating pro-

66 AMPKalpha1 reduced the level of p27(Kip1), a cyclin-dependent kinase inhibitor, and increased the lev

67 specific upregulation of p57Kip2, a Cip/Kip cyclin-dependent kinase inhibitor, and we identified thi

68 We confirmed that AT7159 (cyclin-dependent kinase inhibitor), AT9283, (Janus kinas

69 cribed mechanisms involving the induction of cyclin-dependent kinase inhibitors but also by the recru

70 mechanisms, including YAP/TAZ signaling and cyclin-dependent kinase inhibitors, by blocking entry in

71 iferation, but the induction of TGF-beta and cyclin-dependent kinase inhibitors causes a cell cycle a

72 These include the cyclin-dependent kinase inhibitor (CDKI) p18INK4c, the m

73 g a model of resistance to a pharmacological cyclin-dependent kinase inhibitor (CDKi), we show that t

74 inary efforts have led to the development of Cyclin-Dependent Kinase inhibitors (CDKi's) as small mol

75 Previous studies showed that cyclin-dependent kinase inhibitors (CDKI) induce autopha

76 ich normally regulates cell cycle inhibitory cyclin-dependent kinase inhibitors (cdki).

77 ase 4 and 6, and increased the expression of cyclin dependent kinase inhibitors (CDKIs), p21 and p27.

78 Cyclin-dependent kinase inhibitors (CDKis) are known inh

79 on of its target protein-coding genes (i.e., cyclin-dependent kinase inhibitor [Cdkn]1b/p27, Cdkn1c/p

80 mediates GC formation through repression of cyclin-dependent kinase inhibitor CDKN1A (p21(Cip1)).

81 repressor, which leads to expression of the cyclin-dependent kinase inhibitor CDKN1A (p21(CIP1/WAF1)

82 Runx1 deletion resulted in cyclin-dependent kinase inhibitor Cdkn1a (p21) upregulat

83 In particular, we found that the cyclin-dependent kinase inhibitor CDKN1A (p21) was overe

84 inogenesis that depends, in part, on loss of cyclin-dependent kinase inhibitor CDKN1A.

85 Its KD results in accumulation of the cyclin-dependent kinase inhibitors CDKN1A and CDKN1B, G(

86 its downstream targets, cJUN, ATF3, and the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B.

87 lial marker expression, and late increase in cyclin-dependent kinase inhibitor CDKN1B (p27) protein-w

88 Here we increase levels of the cyclin-dependent kinase inhibitor Cdkn1b (p27kip1) in ad

89 Both SCF complexes targeted the cyclin-dependent kinase inhibitor Cdkn1b for polyubiquit

90 We identified the cyclin-dependent kinase inhibitor Cdkn1c (p57) as a key

91 Hairy and Enhancer of Split 1 (HES1) and the cyclin-dependent kinase inhibitor CDKN1C/p57 as novel ta

92 cell-cycle transition through repression of cyclin-dependent kinase inhibitors Cdkn2a and Cdkn2b, an

93 e show that Hoxa9 represses the locus of the cyclin-dependent kinase inhibitors Cdkn2a/b in concert w

94 gnature correlates with the induction of the cyclin-dependent kinase inhibitors CDKN2D (p19(INK4d)) a

95 ty, and resulting in accumulation of p53 and cyclin-dependent kinase inhibitors, cell cycle arrest, a

96 a protein expression and increased levels of cyclin-dependent kinase inhibitors, CIP1 (p21) and KIP1

97 G1 arrest in part through regulation of the cyclin-dependent kinase inhibitor cki-1.

98 ntify the p21(Cip1)/p27(Kip1)/p57(Kip2)-like cyclin-dependent kinase inhibitor (CKI) Dacapo (Dap) as

99 Peptide treatment induced cyclin-dependent kinase inhibitor (CKI) p16(INK4a) prote

100 Here, we defined the roles of cyclin-dependent kinase inhibitor (CKI) p57(KIP2), an im

101 e hypothesize that this is due to a weakened cyclin-dependent kinase inhibitor (CKI)-cyclin-dependent

102 ar access of signaling cargos and sequesters cyclin-dependent kinase inhibitors (CKIs) involved in ET

103 tein suppresses the transcription of several cyclin-dependent kinase inhibitors (CKIs) via binding to

104 lation of the tumor suppressors pRb, Cip/Kip cyclin-dependent kinase inhibitors (CKIs), and CDH1, and

105 ated PCD through a physical interaction with cyclin-dependent kinase inhibitors (CKIs).

106 Systemic administration of the selective cyclin-dependent kinase inhibitor CR8 after SCI signific

107 The cyclin-dependent kinase inhibitor Dacapo (Dap), a p21/p2

108 Here, we show that the cyclin-dependent kinase inhibitor Dacapo (Dap; ortholog

109 Using the cyclin-dependent kinase inhibitor dinaciclib, which down

110 Furthermore p21, a cyclin-dependent kinase inhibitor downstream of S100/A11

111 Here, we address how interactions between cyclin-dependent kinase inhibitors essential for myogeni

112 oma cation channel complex, had no effect on cyclin-dependent kinase inhibitor expression.

113 the redox-reactive thalidomide CPS49 and the cyclin-dependent kinase inhibitor flavopiridol as a sele

114 ase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patien

115 matic mutations and deletions in CDKN1B, the cyclin-dependent kinase inhibitor gene, which encodes p2

116 associated with reduced aortic expression of cyclin-dependent kinase inhibitor genes p19Arf and p15In

117 the mRNA expression of osteoblast marker and cyclin-dependent kinase inhibitor genes were all reduced

118 Two homologous cyclin-dependent kinase inhibitor genes, SIAMESE (SIM) a

119 However, whether cyclin-dependent kinase inhibitor I induction by IP6 pla

120 CDKN1C/P57 is a cyclin-dependent kinase inhibitor implicated in differen

121 s on the role of one RNA in silencing p15, a cyclin-dependent kinase inhibitor implicated in leukaemi

122 enetic inactivation of p16(ink4a) encoding a cyclin-dependent kinase inhibitor implicated in neuronal

123 reveals differential roles of two homologous cyclin-dependent kinase inhibitors in regulating cell-cy

124 viral cyclin has reduced sensitivity to host cyclin-dependent kinase inhibitors in vitro; however, th

125 to the down-regulation of p21(WAF1/cip1), a cyclin-dependent kinase inhibitor, in intestinal epithel

126 as its downstream target, the p21(Cip1/Waf1) cyclin-dependent kinase inhibitor, in the regulation of

127 eased expression of PDGFRbeta and p57kip2, a cyclin-dependent kinase inhibitor, in these cells.

128 Hdac3 overexpression inhibits several cyclin-dependent kinase inhibitors, including Cdkn1a, Cd

129 Cyclin-dependent kinase inhibitors, including p21Cip1, a

130 Messenger RNA levels of cyclin-dependent kinase inhibitors increased progressive

131 from an alternative reading frame of the p16 cyclin-dependent kinase inhibitor INK4a/ARF gene.

132 liferation is due in part to derepression of cyclin-dependent kinase inhibitors Ink4a/b, while ineffe

133 Specifically, encapsulation of dinaciclib, a cyclin-dependent kinase inhibitor, into PD-L1-targeted L

134 We have found that the expression of p21, a cyclin-dependent kinase inhibitor involved in cell cycle

135 The stability of p21, a cyclin-dependent kinase inhibitor, is highly regulated b

136 p21, a cyclin-dependent kinase inhibitor, is necessary for prop

137 was reported to control the stability of the CYCLIN-DEPENDENT KINASE inhibitor KIP-RELATED PROTEIN (K

138 of FBL17 increases the stability of the CDK (CYCLIN-DEPENDENT KINASE) inhibitor KIP-RELATED PROTEIN2

139 ost inhibitors p27(Kip1) and p18(INK4c), two cyclin-dependent kinase inhibitors known to be important

140 nt of corneal transparency without affecting cyclin-dependent kinase inhibitor levels in Vim(-/-) mic

141 ly due to a failure in proliferation; p27, a cyclin dependent kinase inhibitor, normally undetectable

142 wt cells, which also correlated with p27/p21 cyclin-dependent kinase inhibitor over-expression.

143 stically, this involved up-regulation of the cyclin-dependent kinase inhibitor p15 and the proapoptot

144 k genotype does not affect the activation of cyclin-dependent kinase inhibitors p15 and p16 by interf

145 senescence, accompanied by the induction of cyclin-dependent kinase inhibitors p15(INK4B), p16(INK4A

146 cytostatic program include activation of the cyclin-dependent kinase inhibitors, p15(Ink4B) and p21(W

147 xpression of two other cell cycle inhibitory cyclin-dependent kinase inhibitors, p15Ink4b (Cdkn2b) an

148 -->S cell cycle progression by targeting the cyclin-dependent kinase inhibitor p16(INK4a) (p16).

149 on of the Ink4a/Arf locus, which encodes the cyclin-dependent kinase inhibitor p16(INK4a) and tumor s

150 Mutations or deletions in the cyclin-dependent kinase inhibitor p16(INK4A) are associa

151 argeting the CDKN2A locus, which encodes the cyclin-dependent kinase inhibitor p16, decreased CDKN2A

152 (stasis) associated with elevated levels of cyclin-dependent kinase inhibitors p16 and/or p21.

153 Restored expression of the cyclin-dependent kinase inhibitor p16INK4a abrogated the

154 l -74 C-to-T mutation in the promoter of the cyclin-dependent kinase inhibitor p18(Ink4c) (p18) gene

155 nalysis presents Cdkn2c, a gene encoding for cyclin-dependent kinase inhibitor p18(INK4c) (p18), as t

156 he expression of Cdkn2c, a gene encoding for cyclin-dependent kinase inhibitor p18(Ink4c) and located

157 cyclin functions specifically to bypass the cyclin-dependent kinase inhibitor p18(INK4c), revealing

158 the ATM inhibitor showed increased levels of cyclin-dependent kinase inhibitor p19(INK4D), reduced le

159 l cycle regulators cyclins D, A2, and B2 and cyclin-dependent kinase inhibitor p20 in brain tissue.

160 f HIV-1 coreceptors and up-regulation of the cyclin-dependent kinase inhibitor p21 (also known as cip

161 ith strong and selective upregulation of the cyclin-dependent kinase inhibitor p21 (also known as cip

162 ncreased transcription and expression of the cyclin-dependent kinase inhibitor p21 and consequent cel

163 ciated with HER2-induced accumulation of the cyclin-dependent kinase inhibitor p21 and decrease in th

164 rrest accompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expr

165 st cancer cells, increased expression of the cyclin-dependent kinase inhibitor p21 but had no effect

166 damage response signaling pathway involving cyclin-dependent kinase inhibitor p21 expression and het

167 ed expression of the key p53 target gene and cyclin-dependent kinase inhibitor p21 in HCT116 cells, p

168 We found that PCBP4 expression decreases cyclin-dependent kinase inhibitor p21 induction in respo

169 We have previously shown that the cyclin-dependent kinase inhibitor p21 inhibits the repli

170 The cyclin-dependent kinase inhibitor p21 is an important pl

171 The cyclin-dependent kinase inhibitor p21 is an important tr

172 Here, we demonstrate that the cyclin-dependent kinase inhibitor p21 is both necessary

173 usly, we demonstrated that expression of the cyclin-dependent kinase inhibitor p21 is reduced in syno

174 d at the promoters of the genes encoding the cyclin-dependent kinase inhibitor p21 or the transcripti

175 an E3 ubiquitin ligase, CRL2(LRR1), for the cyclin-dependent kinase inhibitor p21 that specifically

176 sed expression of proapoptotic genes and the cyclin-dependent kinase inhibitor p21 was seen.

177 OS) and by maintaining the expression of the cyclin-dependent kinase inhibitor p21(CDKN1A).

178 rentiation of MLL-AF9 blasts, which requires cyclin-dependent kinase inhibitor p21(Cip1) (Cdkn1a) act

179 vely lower in HTSF compared to NADF, and the cyclin-dependent kinase inhibitor p21(cip1) is upregulat

180 The cyclin-dependent kinase inhibitor p21(Cip1) plays an imp

181 stoma suppressor protein pRb, as well as the cyclin-dependent kinase inhibitor p21(Cip1).

182 nstream-regulated gene 1 and upregulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1) while d

183 ited cell proliferation and up-regulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1).

184 rminus deficiency promotes expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) (Cdkn1a

185 liferation of ATC cells via induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) (p21).

186 t transcription of both IkappaBalpha and the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and ind

187 The cyclin-dependent kinase inhibitor p21(Waf1/Cip1) is a ma

188 ntly increases transcription and activity of cyclin-dependent kinase inhibitor p21(WAF1/CIP1), leadin

189 the nitric oxide-dependent induction of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1).

190 rt that cellular mRNAs encoding the cellular cyclin-dependent kinase inhibitor p21, a key inducer of

191 hat fine-tuning the expression levels of the cyclin-dependent kinase inhibitor p21, a p53 target gene

192 tion, stabilization of p53, induction of the cyclin-dependent kinase inhibitor p21, and homologous re

193 9, it inhibits BMP-mediated induction of the cyclin-dependent kinase inhibitor p21, and it reverses B

194 hat directly regulates the expression of the cyclin-dependent kinase inhibitor p21, independently of

195 A key target of PC1, the cyclin-dependent kinase inhibitor p21, is also up-regula

196 evels of bone morphogenetic proteins and the cyclin-dependent kinase inhibitor p21, which might contr

197 d resulted in decreased transcription of the cyclin-dependent kinase inhibitor p21.

198 ession of proarrest gene targets such as the cyclin-dependent kinase inhibitor p21.

199 and one of its transcriptional targets, the cyclin-dependent kinase inhibitor p21.

200 d DNA synthesis through the induction of the cyclin-dependent kinase inhibitor p21.

201 ultiple targets of the family, including the cyclin-dependent kinase inhibitor p21/CDKN1A.

202 53 response, accompanied by induction of the cyclin-dependent kinase inhibitor p21/CIP1, which can be

203 endent on increased expression of the cyclin/cyclin-dependent kinase inhibitor p21/WAF1/CIP1.

204 le phase, and the expression of pAkt and the cyclin-dependent kinase inhibitors p21 and p27 was incre

205 ignificant increase in the expression of the cyclin-dependent kinase inhibitors p21 and p27, and a de

206 e/AKT signaling pathway, upregulation of the cyclin-dependent kinase inhibitors p21 and p27, antiprol

207 bited proliferation through induction of the cyclin-dependent kinase inhibitors p21 and p27.

208 fect was mediated through decreased level of cyclin-dependent kinase inhibitors p21 and p27.

209 xygenase-1, programmed cell death 4, and the cyclin-dependent kinase inhibitors p21, p27, and p57.

210 e inducible Src homology 2-containing genes, cyclin-dependent kinase inhibitors p21, p57, calmodulin

211 phate (IP6) causes G(1) arrest and increases cyclin-dependent kinase inhibitors p21/Cip1 and p27/Kip1

212 in part through decreasing expression of the cyclin dependent kinase inhibitor, p21.

213 ectopic expression of p16(INK4a) and another cyclin-dependent kinase inhibitor, p21(CIP1/WAF1), induc

214 with the p53-independent upregulation of the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1) (p21).

215 r senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1).

216 ng p53-induced protein with death domain and cyclin-dependent kinase inhibitor, p21.

217 egulation of cyclin D1, up-regulation of the cyclin-dependent kinase inhibitors, p21(cip1.) and p16(I

218 by hyperactivated NF-kappaB and mediated by cyclin-dependent kinase inhibitors, p21(CIP1/WAF1) and p

219 ggers a host senescence response mediated by cyclin-dependent kinase inhibitors: p21(CIP1/WAF1) (p21)

220 o a partial G1/S arrest and induction of the cyclin-dependent kinase inhibitor, p21cip/CDKN1A.

221 We found that the expression of cyclin-dependent kinase inhibitor p21cip1 was impaired i

222 ers led to compensatory up-regulation of the cyclin-dependent kinase inhibitor p21Cip1.

223 , processes also under the regulation of the cyclin-dependent kinase inhibitor p21Cip1.

224 is likely due to increased expression of the cyclin-dependent kinase inhibitors p21Cip1/Waf1 and p19I

225 plexes bind a promoter motif and repress the cyclin-dependent kinase inhibitor p21WAF1 in both human

226 an increase in the tumor protein p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1, which ar

227 C-mediated transcriptional inhibition of the cyclin-dependent kinase inhibitors p21WAF1 and p27KIP2,

228 ng the receptors EGFR, ERBB3 (HER3), and the cyclin-dependent kinase inhibitor p27 (CDKN1B) was found

229 1 and E1 while suppressing the expression of cyclin-dependent kinase inhibitor p27 (CDKN1B), each con

230 rapamycin, mTOR) and altered activity of the cyclin-dependent kinase inhibitor p27 (p27(kip1)) and ex

231 ell proliferation and elevated expression of cyclin-dependent kinase inhibitor P27 (P27KIP1) in a GEF

232 Down-regulation of the cyclin-dependent kinase inhibitor p27 alone significantl

233 C/C(Cdh1)), resulting in accumulation of the cyclin-dependent kinase inhibitor p27 and a concomitant

234 LMP1 decreases expression of the cyclin-dependent kinase inhibitor p27 and increases the

235 kdown results in the nuclear localization of cyclin-dependent kinase inhibitor p27 and prevents the p

236 The cyclin-dependent kinase inhibitor p27 is a key regulator

237 d with rapamycin produced an increase in the cyclin-dependent kinase inhibitor p27(Kip), through a de

238 s generated an adenovirus that expresses the cyclin-dependent kinase inhibitor p27(Kip1) (p27) and be

239 Cyclin-dependent kinase inhibitor p27(kip1) (p27) has re

240 l endothelial cells (rCECs) by degrading the cyclin-dependent kinase inhibitor p27(Kip1) (p27) throug

241 used an adenoviral (Ad) vector that encodes cyclin-dependent kinase inhibitor p27(Kip1) (p27) with t

242 which is cytoplasmic mislocalization of the cyclin-dependent kinase inhibitor p27(Kip1) (p27).

243 tating translation of mRNAs encoding for the cyclin-dependent kinase inhibitor p27(Kip1) and antiapop

244 ors of cell proliferation and migration, the cyclin-dependent kinase inhibitor p27(Kip1) and the micr

245 EFs leads to an increase in the level of the cyclin-dependent kinase inhibitor p27(Kip1) and to rapid

246 Here, we have identified the cyclin-dependent kinase inhibitor p27(Kip1) as a critica

247 ion and hyperproliferation by downregulating cyclin-dependent kinase inhibitor p27(kip1) in a proteas

248 colleagues (3121-3134) demonstrate that the cyclin-dependent kinase inhibitor p27(Kip1) is ubiquityl

249 The cyclin-dependent kinase inhibitor p27(Kip1) plays a crit

250 that HINT1 regulates cellular levels of the cyclin-dependent kinase inhibitor p27(KIP1) through mult

251 g for the proliferation marker Ki-67 and the cyclin-dependent kinase inhibitor p27(Kip1) were perform

252 orroborated in this study by coexpression of cyclin-dependent kinase inhibitor p27(Kip1)), we hypothe

253 s are actively cycling, but some express the cyclin-dependent kinase inhibitor p27(Kip1), and are pre

254 s T-cell proliferation by the destruction of cyclin-dependent kinase inhibitor p27(kip1), and deletio

255 One of these, miR-221, a regulator of the cyclin-dependent kinase inhibitor p27(kip1), displayed r

256 ivation, and cytoplasmic localization of the cyclin-dependent kinase inhibitor p27(Kip1), which has b

257 endogenous expression of the E2F1-regulated cyclin-dependent kinase inhibitor p27(Kip1).

258 possess significantly reduced levels of the cyclin-dependent kinase inhibitor p27(kip1).

259 ion in part through the up-regulation of the cyclin-dependent kinase inhibitor p27(kip1).

260 t ultimately involves destabilization of the cyclin-dependent kinase inhibitor p27(Kip1).

261 re, attributed to elevated expression of the cyclin-dependent kinase inhibitor p27, a Siah2 substrate

262 osol, which causes hyper-accumulation of the cyclin-dependent kinase inhibitor p27, leading to mitoti

263 ar localization relies on its binding to the cyclin-dependent kinase inhibitor p27.

264 lls were proliferative, most coexpressed the cyclin-dependent kinase inhibitor p27/Kip1.

265 regulation of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1.

266 differentiation by modulating expression of cyclin-dependent kinase inhibitor p27/p57 and E3 ubiquit

267 dicted to target the cell growth suppressive cyclin-dependent kinase inhibitors p27 and p57.

268 jugating E3 ligase Skp2 and up-regulation of cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip

269 and (3) an increase in the expression of the cyclin-dependent kinase inhibitors p27(kip1) and p21(cip

270 n by causing a decrease in expression of the cyclin dependent-kinase inhibitor p27Kip1.

271 ors of cell proliferation and migration, the cyclin-dependent kinase inhibitor p27Kip1 and the microt

272 N-myc represses the expression of the cyclin-dependent kinase inhibitor p27Kip1 but acts indep

273 The cyclin-dependent kinase inhibitor p57 is highly expresse

274 bited a significant decrease in the level of cyclin-dependent kinase inhibitor p57(KIP2) and an incre

275 In addition, our data suggest that cyclin-dependent kinase inhibitor p57(Kip2) and vascular

276 The cyclin-dependent kinase inhibitor p57(kip2) is encoded b

277 s the expression of the beta-cell-associated cyclin-dependent kinase inhibitor p57kip2, and simultane

278 gnaling reduced expression of N-cad, and the cyclin dependent kinase inhibitor, p57Kip2, indicating a

279 -line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib.

280 rest mediated by the ROS-activated SMR5/SMR7 cyclin-dependent kinase inhibitors pathway in the intera

281 P21, a cyclin-dependent kinase inhibitor, plays a pivotal role

282 associated with reduced expression of p21, a cyclin-dependent kinase inhibitor previously implicated

283 TX-1 and benzamil up-regulated expression of cyclin-dependent kinase inhibitor proteins p21(Cip1) and

284 e, we show that polymersomes can deliver the cyclin-dependent kinase inhibitor (R)-roscovitine into h

285 F-box protein) recognizes its substrate, the cyclin-dependent kinase inhibitor Sic1, in a multisite p

286 iquitinylates many substrates, including the cyclin-dependent kinase inhibitor Sic1, targeting it for

287 his study, we show that dinaciclib, a potent cyclin dependent kinase inhibitor, significantly increas

288 The p16INK4a protein is a principal cyclin-dependent kinase inhibitor that decelerates the c

289 p21(Waf1/Cip1/Sdi1) is a cyclin-dependent kinase inhibitor that mediates cell cyc

290 oRNAs, and represses expression of Cdkn1a, a cyclin-dependent kinase inhibitor that negatively regula

291 Among cyclin-dependent kinase inhibitors that control the G1 p

292 ctor of tumor suppressors and functions as a cyclin-dependent kinase inhibitor to block cellular prol

293 ore rearrangement and release of sequestered cyclin-dependent kinase inhibitors to elicit immunity an

294 Senescent cells often express p16(INK4a), a cyclin-dependent kinase inhibitor, tumor suppressor, and

295 Expression of p57kip2, a BMP10-regulated cyclin-dependent kinase inhibitor, was induced in Myocd-

296 e SIAMESE/SIAMESE-RELATED (SIM/SMR) class of cyclin-dependent kinase inhibitors were discovered that

297 Levels of p21 (Cip1/WAF1), a cyclin-dependent kinase inhibitor, were decreased in aff

298 The p16(INK4a) (p16) is a cyclin-dependent kinase inhibitor, which has been evalua

299 lation of the Skp2-degradation target p27, a cyclin-dependent kinase inhibitor, which was confirmed a

300 e switching, the Xenopus laevis Cip/Kip-type cyclin-dependent kinase inhibitor Xic1 associates with t